On June 3, JD Health fell 3.52% in regular trading, trading at HKD 38.34/share, with trading volume of HKD 89.0045 million. The broader Internet & Direct Marketing Retail sector declined in tandem, with Meituan down 4.5%, JD Group down 3.66%, Ali Health down 2.62%, and Ping An Good Doctor down 2.66%.

On the news front, the National Medical Products Administration officially implemented the Compliance Guide for Online Retail of Prescription Drugs, which mandates that prescription reviews must be conducted by licensed pharmacists, explicitly banning AI-assisted prescription approval. The regulation also prohibits displaying prescription drugs on platform homepages and bars promotional methods including giveaways and livestreaming for such products.

Market testing shows that high-demand GLP-1 weight-loss injections can no longer be directly purchased online from platforms including JD, with sales pathways already adjusted. Industry observers note that the new rules effectively dismantle the previous high-efficiency loop of online consultation plus e-prescription plus instant delivery, forcing platforms to shift from a traffic-conversion model back to a compliance-first medical logic, which may structurally compress online prescription drug revenue growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)